{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:39:04Z","timestamp":1769600344895,"version":"3.49.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>The best course of treatment for recurrent ovarian cancer is uncertain. We sought to determine whether secondary cytoreductive surgery for first recurrence of ovarian cancer improves overall survival compared with other treatments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>We assessed survival using Surveillance, Epidemiology and End Results-Medicare data for advanced stage ovarian cancer cases diagnosed from January 1, 1997 to December 31, 2007 with survival data through 2010 using multinomial propensity weighted finite mixture survival regression models to distinguish true from misclassified recurrences. Of 35,995 women ages 66 years and older with ovarian cancer, 3439 underwent optimal primary debulking surgery with 6 cycles of chemotherapy; 2038 experienced a remission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>One thousand six hundred thirty-five of 2038 (80%) women received treatment for recurrence of whom 72% were treated with chemotherapy only, 16% with surgery and chemotherapy and 12% received hospice care. Median survival of women treated with chemotherapy alone, surgery and chemotherapy, or hospice care was 4.1, 5.4, and 2.2 years, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001). Of those receiving no secondary treatments, 75% were likely true nonrecurrences with median survival of 15.9 years and 25% misclassified with 2.4 years survival. Survival among women with recurrence was greater for those treated with surgery and chemotherapy compared with chemotherapy alone (hazard ratio=1.67; 95% confidence interval, 1.13-2.47). Women who were older with more comorbidities and high-grade cancer had worse survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Secondary surgery with chemotherapy to treat recurrent ovarian cancer increases survival by 1.3 years compared with chemotherapy alone and pending ongoing randomized trial results, may be considered a standard of care.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000310","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T18:23:37Z","timestamp":1467915817000},"page":"458-464","source":"Crossref","is-referenced-by-count":16,"title":["Secondary Surgery Versus Chemotherapy for Recurrent Ovarian Cancer"],"prefix":"10.1097","volume":"41","author":[{"given":"Nina A.","family":"Bickell","sequence":"first","affiliation":[{"name":"Population Health Science and Policy, and Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Egorova","sequence":"additional","affiliation":[{"name":"Population Health Science and Policy, and Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Prasad-Hayes","sequence":"additional","affiliation":[{"name":"Obstetrics, Gynecology and Reproductive Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca","family":"Franco","sequence":"additional","affiliation":[{"name":"Population Health Science and Policy, and Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Howell","sequence":"additional","affiliation":[{"name":"Population Health Science and Policy, and Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Wisnivesky","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Partha","family":"Deb","sequence":"additional","affiliation":[{"name":"Department of Economics, Hunter College, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrclinonc.2013.5","article-title":"Latest research and treatment of advanced-stage epithelial ovarian cancer","volume":"10","author":"Coleman","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/1097-0142(19921015)70:8<2129::AID-CNCR2820700820>3.0.CO;2-U","article-title":"Radical surgical procedure improves survival time in patients with recurrent ovarian cancer","volume":"70","author":"Janicke","year":"1992","journal-title":"Cancer"},{"key":"R4-20230903","first-page":"CD008765","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","volume":"2","author":"Al Rawahi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"15S","key":"R5-20230903","doi-asserted-by":"crossref","first-page":"e15513","DOI":"10.1200\/jco.2012.30.15_suppl.e15513","article-title":"Using hospital claims data to identify ovarian cancer recurrence: a validation study","volume":"30","author":"Livaudais","year":"2012","journal-title":"J Clin Oncol"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X","article-title":"The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma","volume":"88","author":"Eisenkop","year":"2000","journal-title":"Cancer"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/biomet\/87.3.706","article-title":"The role of the propensity score in estimating dose-response functions","volume":"87","author":"Imbens","year":"2000","journal-title":"Biometrika"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/sim.1903","article-title":"Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study","volume":"23","author":"Lunceford","year":"2004","journal-title":"Stat Med"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10549-010-0752-z","article-title":"Population-based survival-cure analysis of ER-negative breast cancer","volume":"123","author":"Huang","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/bjc.2013.523","article-title":"Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer","volume":"109","author":"Joulain","year":"2013","journal-title":"Br J Cancer"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jhealeco.2004.09.012","article-title":"Is prenatal care really ineffective? Or, is the \u2018devil\u2019 in the distribution?","volume":"24","author":"Conway","year":"2005","journal-title":"J Health Econ"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/jae.3950080407","article-title":"A latent class poisson regression model for heterogeneous count data","volume":"8","author":"Wedel","year":"1993","journal-title":"J Appl Econom"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/(SICI)1099-1255(199705)12:3<313::AID-JAE440>3.0.CO;2-G","article-title":"Demand for medical care by the elderly: a finite mixture approach","volume":"12","author":"Deb","year":"1997","journal-title":"J Appl Econ"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1001\/jama.283.22.2975","article-title":"Are increasing 5-year survival rates evidence of success against cancer?","volume":"283","author":"Welch","year":"2000","journal-title":"JAMA"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2407-14-22","article-title":"Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study","volume":"14","author":"Van De Laar","year":"2014","journal-title":"BMC Cancer"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/AOG.0b013e3182a92011","article-title":"Racial disparities in the treatment of advanced epithelial ovarian cancer","volume":"122","author":"Howell","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/jso.20932","article-title":"Racial disparities in surgical treatment and survival of epithelial ovarian cancer in United States","volume":"97","author":"Chan","year":"2008","journal-title":"J Surg Oncol"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ygyno.2010.12.347","article-title":"Racial disparities in ovarian cancer surgical care: a population-based analysis","volume":"121","author":"Bristow","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ygyno.2011.03.022","article-title":"Trends in treatment of advanced epithelial ovarian cancer in the Medicare population","volume":"122","author":"Thrall","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ygyno.2012.02.033","article-title":"Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands","volume":"125","author":"Van Altena","year":"2012","journal-title":"Gynecol Oncol"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2013.08.035","article-title":"Racial disparities and patterns of ovarian cancer surgical care in California","volume":"132","author":"Liu","year":"2014","journal-title":"Gynecol Oncol"},{"key":"R27-20230903","doi-asserted-by":"crossref","first-page":"188.el","DOI":"10.1016\/j.ajog.2014.08.016","article-title":"Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas","volume":"212","author":"Usach","year":"2015","journal-title":"Am J Obstet Gynecol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201805000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T03:04:37Z","timestamp":1693710277000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201805000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000310","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}